Abstract: Continuous cell lines of genetically stable fused cell hybrids capable of producing large amounts of monoclonal antibodies against specific viruses and their antigenic determinants have been developed. The cell lines are fused cell hybrids between viral antibody producing cells and myeloma cells. Fused cell hybrids between influenza virus-primed mouse spleen cells and mouse myeloma cells can be maintained indefinitely in culture and continue to produce large amounts of anti-influenza antibody.

Abstract: Antibodies demonstrating a specificity for malignant tumors are produced by somatic cell hybrids between hypoxanthine phosphoribosyltransferase deficient myeloma cells and spleen or lymph cells derived from an animal previously primed with tumor cells.

Abstract: A virus-lysed tumor cell vaccine is an active immunotherapeutic agent against tumors in mammals. In particular, a vaccine based upon vaccinia virus-lysed, species-specific tumor cells is an effective stimulator of the immune response in mammals, and a vaccine based upon vaccinia virus-lysed spontaneously arising tumor cells is an effective stimulator of the immune response in some human cancer patients. A process for preparing the vaccine by viral oncolysis is also disclosed. Tumor cells are removed from a mammal, the cells are cultured in a culture medium and infected with live vaccinia virus. Viral oncolysis occurs during incubation and the resulting viral oncolysate, after extraction, may be injected into mammals to stimulate the immune response mechanism.

Abstract: A cytomegalovirus (CMV) vaccine, capable of inducing immunity in humans against cytomegalic inclusion disease (CID), without spread to contacts and with minimal excretion of the virus, is prepared by serially passaging virulent CMV in human diploid lung fibroblasts.